Last reviewed · How we verify
AMG 410
Antibody-drug conjugate targeting fibroblast growth factor receptor 3 (FGFR3)
Antibody-drug conjugate targeting fibroblast growth factor receptor 3 (FGFR3) Used for Non-small cell lung cancer.
At a glance
| Generic name | AMG 410 |
|---|---|
| Sponsor | Amgen |
| Drug class | Antibody-drug conjugate |
| Target | FGFR3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AMG 410 is a monoclonal antibody-drug conjugate that targets FGFR3, a receptor tyrosine kinase involved in the proliferation and survival of cancer cells.
Approved indications
- Non-small cell lung cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMG 410 CI brief — competitive landscape report
- AMG 410 updates RSS · CI watch RSS
- Amgen portfolio CI